{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:56:58Z","timestamp":1791601018714,"version":"4.3.4"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Avibactam, a non-\u03b2-lactam \u03b2-lactamase inhibitor with activity against extended-spectrum \u03b2-lactamases (ESBLs), KPC, AmpC, and some OXA enzymes, extends the antibacterial activity of ceftazidime against most ceftazidime-resistant organisms producing these enzymes. In this study, the bactericidal activity of ceftazidime-avibactam against 18\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n                    isolates and 15\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n                    isolates, including wild-type isolates and ESBL, KPC, and\/or AmpC producers, was evaluated. Ceftazidime-avibactam MICs (0.016 to 32 \u03bcg\/ml) were lower than those for ceftazidime alone (0.06 to \u2265256 \u03bcg\/ml) against all isolates except for 2\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n                    isolates (1\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>VIM<\/jats:sub>\n                    -positive isolate and 1\n                    <jats:italic>bla<\/jats:italic>\n                    <jats:sub>OXA-23<\/jats:sub>\n                    -positive isolate). The minimum bactericidal concentration\/MIC ratios of ceftazidime-avibactam were \u22644 for all isolates, indicating bactericidal activity. Human serum and human serum albumin had a minimal effect on ceftazidime-avibactam MICs. Ceftazidime-avibactam time-kill kinetics were evaluated at low MIC multiples and showed time-dependent reductions in the number of CFU\/ml from 0 to 6 h for all strains tested. A \u22653-log\n                    <jats:sub>10<\/jats:sub>\n                    decrease in the number of CFU\/ml was observed at 6 h for all\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n                    , and a 2-log\n                    <jats:sub>10<\/jats:sub>\n                    reduction in the number of CFU\/ml was observed at 6 h for 3 of the 6\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n                    isolates. Regrowth was noted at 24 h for some of the isolates tested in time-kill assays. These data demonstrate the potent bactericidal activity of ceftazidime-avibactam and support the continued clinical development of ceftazidime-avibactam as a new treatment option for infections caused by\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae<\/jats:named-content>\n                    and\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n                    , including isolates resistant to ceftazidime by mechanisms dependent on avibactam-sensitive \u03b2-lactamases.\n                  <\/jats:p>","DOI":"10.1128\/aac.02894-14","type":"journal-article","created":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T02:08:33Z","timestamp":1403575713000},"page":"5297-5305","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":105,"title":["Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against \u03b2-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa"],"prefix":"10.1128","volume":"58","author":[{"given":"Tiffany R.","family":"Keepers","sequence":"first","affiliation":[{"name":"Cerexa, Inc., Oakland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Gomez","sequence":"additional","affiliation":[{"name":"Cerexa, Inc., Oakland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Celeri","sequence":"additional","affiliation":[{"name":"Cerexa, Inc., Oakland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wright W.","family":"Nichols","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals LP, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Krause","sequence":"additional","affiliation":[{"name":"Cerexa, Inc., Oakland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Antibiotic resistance threats in the United States, 2013","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/13895575113139990074"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00826-13"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-13"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000145"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_2_8_2","volume-title":"Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother.","author":"Keepers TR","year":"2012","unstructured":"KeepersTRGomezMNicholsWWKrauseKM. 2012. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1162."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks156"},{"key":"e_1_3_2_10_2","volume-title":"Check-MDR CT101 user manual","author":"Check-Points Health BV","year":"2012","unstructured":"Check-Points Health BV. 2012. Check-MDR CT101 user manual. Check-Points Health BV, Wageningen, The Netherlands."},{"key":"e_1_3_2_11_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_12_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_13_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20149th ed. CLSI document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u20149th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_14_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents\u2014approved guideline. CLSI document M26-A","author":"Clinical and Laboratory Standards Institute","year":"1999","unstructured":"Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents\u2014approved guideline. CLSI document M26-A. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.04.011"},{"key":"e_1_3_2_16_2","volume-title":"Ceftriaxone for injection, USP, package insert","author":"Sagent Pharmaceuticals","year":"2011","unstructured":"Sagent Pharmaceuticals. 2011. Ceftriaxone for injection, USP, package insert. Sagent Pharmaceuticals, Schaumburg, IL."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-08"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00762-13"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_20_2","volume-title":"Ceftazidime for injection, USP, package insert","author":"Sagent Pharmaceuticals","year":"2012","unstructured":"Sagent Pharmaceuticals. 2012. Ceftazidime for injection, USP, package insert. Sagent Pharmaceuticals, Schaumburg, IL."},{"key":"e_1_3_2_21_2","volume-title":"Piperacillin and tazobactam for injection, USP, package insert","author":"Sagent Pharmaceuticals","year":"2012","unstructured":"Sagent Pharmaceuticals. 2012. Piperacillin and tazobactam for injection, USP, package insert. Sagent Pharmaceuticals, Schaumburg, IL."},{"key":"e_1_3_2_22_2","volume-title":"Merrem\u00ae IV (meropenem for injection) package insert","author":"AstraZeneca Pharmaceuticals LP","year":"2013","unstructured":"AstraZeneca Pharmaceuticals LP. 2013. Merrem\u00ae IV (meropenem for injection) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, DE."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06426-11"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01114-09"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.11.007"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr045"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4589-4596.2004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01718-12"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05682-11"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn425"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.905-909.2003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01190-09"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-12"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02161-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02894-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02894-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:47:06Z","timestamp":1645465626000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02894-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/AAC.02894-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02894-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"2014-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}